The prostate cancer prevention trial: Current status

Betsy Higgins, Ian M. Thompson, Neil Fleshner, Bradley H Pollock, Leslie G. Ford, Eric Klein, E. David Crawford

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: The rationale, design considerations and current status of the Prostate Cancer Prevention Trial (PCPT) are presented. Materials and Methods: The design considerations for a prevention study involving finasteride were reviewed. Most notable was the end of study biopsy planned for all participants to eliminate any detection bias caused by the effect of finasteride on prostate specific antigen. Results: During a 3-year period 18,882 men were randomized in the PCPT. The final end of study biopsy is planned for May 2004. The study was closed 15 months before the final anticipated participant biopsy by the independent Data and Safety Monitoring Committee due to a 24.8% reduction in prostate cancer with finasteride. Conclusions: The extraordinary accrual of PCPT of healthy men in a prospective study to test an intervention for prostate cancer prevention illustrates the potential for future studies. The positive results of the trial as well as many observations that have been made of the study population argue for increased emphasis on prevention research for highly prevalent genitourinary malignancies.

Original languageEnglish (US)
JournalJournal of Urology
Volume171
Issue number2 II
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Finasteride
Biopsy
Clinical Trials Data Monitoring Committees
Prostate-Specific Antigen
Prospective Studies
Safety
Research
Population
Neoplasms

Keywords

  • Clinical trials
  • Prevention
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Higgins, B., Thompson, I. M., Fleshner, N., Pollock, B. H., Ford, L. G., Klein, E., & Crawford, E. D. (2004). The prostate cancer prevention trial: Current status. Journal of Urology, 171(2 II). https://doi.org/10.1097/01.ju.0000107440.15626.11

The prostate cancer prevention trial : Current status. / Higgins, Betsy; Thompson, Ian M.; Fleshner, Neil; Pollock, Bradley H; Ford, Leslie G.; Klein, Eric; Crawford, E. David.

In: Journal of Urology, Vol. 171, No. 2 II, 02.2004.

Research output: Contribution to journalArticle

Higgins, B, Thompson, IM, Fleshner, N, Pollock, BH, Ford, LG, Klein, E & Crawford, ED 2004, 'The prostate cancer prevention trial: Current status', Journal of Urology, vol. 171, no. 2 II. https://doi.org/10.1097/01.ju.0000107440.15626.11
Higgins, Betsy ; Thompson, Ian M. ; Fleshner, Neil ; Pollock, Bradley H ; Ford, Leslie G. ; Klein, Eric ; Crawford, E. David. / The prostate cancer prevention trial : Current status. In: Journal of Urology. 2004 ; Vol. 171, No. 2 II.
@article{878bdd57964049758e8499270defdbd7,
title = "The prostate cancer prevention trial: Current status",
abstract = "Purpose: The rationale, design considerations and current status of the Prostate Cancer Prevention Trial (PCPT) are presented. Materials and Methods: The design considerations for a prevention study involving finasteride were reviewed. Most notable was the end of study biopsy planned for all participants to eliminate any detection bias caused by the effect of finasteride on prostate specific antigen. Results: During a 3-year period 18,882 men were randomized in the PCPT. The final end of study biopsy is planned for May 2004. The study was closed 15 months before the final anticipated participant biopsy by the independent Data and Safety Monitoring Committee due to a 24.8{\%} reduction in prostate cancer with finasteride. Conclusions: The extraordinary accrual of PCPT of healthy men in a prospective study to test an intervention for prostate cancer prevention illustrates the potential for future studies. The positive results of the trial as well as many observations that have been made of the study population argue for increased emphasis on prevention research for highly prevalent genitourinary malignancies.",
keywords = "Clinical trials, Prevention, Prostatic neoplasms",
author = "Betsy Higgins and Thompson, {Ian M.} and Neil Fleshner and Pollock, {Bradley H} and Ford, {Leslie G.} and Eric Klein and Crawford, {E. David}",
year = "2004",
month = "2",
doi = "10.1097/01.ju.0000107440.15626.11",
language = "English (US)",
volume = "171",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2 II",

}

TY - JOUR

T1 - The prostate cancer prevention trial

T2 - Current status

AU - Higgins, Betsy

AU - Thompson, Ian M.

AU - Fleshner, Neil

AU - Pollock, Bradley H

AU - Ford, Leslie G.

AU - Klein, Eric

AU - Crawford, E. David

PY - 2004/2

Y1 - 2004/2

N2 - Purpose: The rationale, design considerations and current status of the Prostate Cancer Prevention Trial (PCPT) are presented. Materials and Methods: The design considerations for a prevention study involving finasteride were reviewed. Most notable was the end of study biopsy planned for all participants to eliminate any detection bias caused by the effect of finasteride on prostate specific antigen. Results: During a 3-year period 18,882 men were randomized in the PCPT. The final end of study biopsy is planned for May 2004. The study was closed 15 months before the final anticipated participant biopsy by the independent Data and Safety Monitoring Committee due to a 24.8% reduction in prostate cancer with finasteride. Conclusions: The extraordinary accrual of PCPT of healthy men in a prospective study to test an intervention for prostate cancer prevention illustrates the potential for future studies. The positive results of the trial as well as many observations that have been made of the study population argue for increased emphasis on prevention research for highly prevalent genitourinary malignancies.

AB - Purpose: The rationale, design considerations and current status of the Prostate Cancer Prevention Trial (PCPT) are presented. Materials and Methods: The design considerations for a prevention study involving finasteride were reviewed. Most notable was the end of study biopsy planned for all participants to eliminate any detection bias caused by the effect of finasteride on prostate specific antigen. Results: During a 3-year period 18,882 men were randomized in the PCPT. The final end of study biopsy is planned for May 2004. The study was closed 15 months before the final anticipated participant biopsy by the independent Data and Safety Monitoring Committee due to a 24.8% reduction in prostate cancer with finasteride. Conclusions: The extraordinary accrual of PCPT of healthy men in a prospective study to test an intervention for prostate cancer prevention illustrates the potential for future studies. The positive results of the trial as well as many observations that have been made of the study population argue for increased emphasis on prevention research for highly prevalent genitourinary malignancies.

KW - Clinical trials

KW - Prevention

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0347759930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347759930&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000107440.15626.11

DO - 10.1097/01.ju.0000107440.15626.11

M3 - Article

C2 - 14713747

AN - SCOPUS:0347759930

VL - 171

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2 II

ER -